requested Dr. Yellapragada Subbarow (of Lederle lab and his friend and colleague at Harvard Medical School) to supply Aminopterin and later Amethopterin (Methotrexate) to conduct trials on to children with leukemia, a diagnosis that was deemed a "death sentence," in 1948. He achieved the world's first partial remission of acute leukemia. He went on to co-found the Dana-Farber Cancer Institute in 1950. Dr. John Enders, his assistant Thomas Weller, and colleague Frederick Robbins, successfully cultured the polio virus in 1949, making possible the development of the Salk and Sabin vaccines for polio. They won the Nobel Prize for their work in 1954. Enders and his team went on to culture the measles virus. Dr. Judah Folkman published "Tumor angiogenesis: Therapeutic implications" in the 1971 November issue of the New England Journal of Medicine. It was the first paper to describe Folkman's theory that tumors recruit new blood vessels to grow. The Boston Brace, a new, lower profile brace for patients with scoliosis was developed by Chief of Orthopedics John E. Hall and orthotist Bill Miller at the Boston Children's scoliosis clinic in 1972. Boston Children's conducted a widespread study on donated teeth from children living in Chelsea and Somerville in the 1970s to study how lead effected children's behavior, development and IQ. The results showed that "children whose teeth had the highest lead levels were far behind those with the lowest on measures including IQ, motor coordination and attentiveness in class." Hypoplastic left heart syndrome, a defect in which an infant is born without a functioning left ventricle was first treated via surgical palliation in 1983. The procedure was the first to palliate what had been a fatal condition. Three years later, in 1986, Children's surgeons performed the hospital's first heart transplant. Later in the year, a 15-month-old patient became the youngest person in New England to receive a heart transplant. Boston Children's Chief of Hematology and Oncology David Nathan recommended for Claudia De Pass, a young patient with sickle cell disease, to try Hydroxyurea, a drug used to treat blood cancer, to treat her sickle cell disease. The treatment worked and Hydroxyurea is now broadly used to treat sickle cell disease. Researchers in neurology and genetics discover the toxicity beta amyloid, a protein that accumulates in the brains of people with Alzheimer's disease, to neurons in 1989. This discovery indicates beta amyloid as the possible cause of the degenerative